Back to top
more

NovoCure Limited (NVCR)

(Real Time Quote from BATS)

$15.81 USD

15.81
301,052

+0.63 (4.15%)

Updated Nov 1, 2024 01:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of 17.65% and 7.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

New Strong Buy Stocks for August 1st

by Zacks Equity Research

NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of 22.50% and 10.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of 16.28% and 5.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Organon's (OGN) first-quarter results are likely to reflect growth in its biosimilars and established brand franchises with lighter fertility product sales amid foreign exchange headwinds.

What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

What's in Store for Cardinal Health (CAH) in Q3 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.

Cencora (COR) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Cencora's (COR) second-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medpace (MEDP) Beats Q1 Earnings Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 30.61% and 0.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for NovoCure (NVCR) points to a 63.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of 15.09% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength?

by Zacks Equity Research

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for NovoCure (NVCR) points to a 105.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of 11.54% and 0.83%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod

by Zacks Equity Research

Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of -8% and 2.38%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Revvity (RVTY) Q2 Earnings Expected to Decline

by Zacks Equity Research

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NovoCure (NVCR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of -38.89% and 4.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?